Dana Inc
Auto Components
Dana Inc (DAN) Stock News
The latest DAN headlines and market coverage — 2 recent stories, updated throughout the day.
- Benzinga·
BURLINGTON STORES REPORTS STRONG FIRST QUARTER SALES AND EARNINGS GROWTH, WELL AHEAD OF GUIDANCE. THIS REPRESENTS THE 14TH CONSECUTIVE QUARTER OF DOUBLE DIGIT EPS GROWTH.
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <ul> <li style="list-style-type:none;"> <ul> <li style="text-align:left;"><strong>Total sales increased 14%, on top of 6% last year </strong></li> <li style="text-align:left;"><strong>Comparable store sales increased 6%</strong></li> <li style="text-align:left;"><strong>Net income was $115 million, and diluted EPS was $1.79 </strong></li> <li style="text-align:left;"><strong>Excluding certain expenses associated with bankruptcy acquired leases: </strong> <ul> <li><strong>Adjusted EPS increased 26% to $2.10, well above guidance</strong></li> <li><strong>Full year adjusted EPS guidance is now $11.45 to $11.80<br /><br /></strong></li> </ul> </li> </ul> </li> </ul> <p align="left">BURLINGTON, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Burlington Stores, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/BURL" rel="nofollow">BURL</a>), a nationally recognized off-price retailer of high-quality, branded apparel, footwear, accessories, and merchandise for the home at everyday low prices, today announced its results for the first quarter ended May 2, 2026.</p> <p align="left">Michael O&#039;Sullivan, CEO, stated, "We are pleased with our strong performance in the first quarter. Adjusted EPS grew 26% versus the first quarter of last year, which represented our 14th consecutive quarter of double digit EPS growth. This track record demonstrates our ability to consistently convert sales into operati
- GlobeNewswire Inc.·
NANOBIOTIX ANNONCE LA PRÉSENTATION DE DONNÉES DE LA PREMIÉRE PARTIE DE L’ÉTUDE CLINIQUE RANDOMISÉE DE PHASE 2 EVALUANT JNJ-1900 (NBTXR3) DANS LES CANCERS DU POUMON DE STADE 3 INOPÉRABLE
Nanobiotix announced early results from the Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer developed in collaboration with Johnson & Johnson, in patients with stage 3 inoperable non-small cell lung cancer. The study showed promising efficacy with an 85.7% overall response rate and 57.1% complete response rate in 7 patients who completed treatment, compared to less than 5% complete response rates with current standard of care.